Respironics wins round in litigation with ResMed:
This article was originally published in Clinica
A district court has dismissed a charge by ResMed against Respironics relating to allegations of patent infringement. The patent covers ResMed's delay timer feature on its devices for the treatment of sleep apnoea. The court has now dismissed all three of the original patents named in the suit which dates from January 1995. Pittsburgh, Pennsylvania-based Respironics is "extremely confident" about one remaining claim, filed in June 1996, and the company plans to seek reimbursement for legal fees. ResMed, of San Diego, California, said it was disappointed by the ruling, but the decision did not affect the validity of the disputed patents. The company plans to appeal at the appropriate time.
You may also be interested in...
A combined final opinion on the European Chemicals Agency’s proposed microplastic restriction is expected from ECHA committees by year-end, at which point the European Commission will consider whether and when microplastic must be removed from all leave-on cosmetic products marketed in the EU.
Butterfly Network’s CEO Laurent Faracci outlines the company’s growth strategy and plans for their “ultrasound-on-a-chip” technology after its merger with blank check company Longview Acquisition Corp. See what the company’s CEO said about it here.
CDC’s Advisory Committee on Immunization Practices votes 13-1 that these two groups be first in line for vaccination once FDA authorizes a vaccine and ACIP recommends it. Goal of vote is to guide health departments in placing vaccine orders.